Meet the Evaluate Team: Magda Lis-Podjaska
Listening to our customers is a big focus for Evaluate. To ensure our solutions are continually evolving to meet market challenges, we find all sorts of ways to understand what our clients want from us. And coordinating all that activity is the delightful Magda Lis-Podjaska, our Global Voice of the Customer Lead. She took time […]
Biopharma Reading List: The Evaluate Top 10 of 2024
Obesity. The Inflation Reduction Act. Orphan Drugs. CDMOs. Successful forecasting techniques. We’ve covered all this and more in our biopharma reports, webinars and analysis throughout 2024. As I’ve had the pleasure of working with our experts to create all this content, I thought year-end was a splendid opportunity to share the most-read pieces of the […]
Three Things we Learned in our Launch Excellence Webinar
Picture the scene. You’ve got a new, hugely promising new drug in the pipeline and all the clinical signs are looking good. Which means you have to start focusing on your launch strategy to ensure commercial success. You need to refine your list of potential opportunities and threats, and develop forecasts that will ensure the […]
Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar
One of the great things about working in the pharma industry is the opportunity to listen to very clever people talking about fascinating topics and the latest trends in the market. Events like BIO-Europe are brilliant for this, and there is always plenty to unpack after the panels, keynotes and fireside chats have ended. Our […]
CDMOs: A Paradigm Change for Pharma?
At the recent CPHI exhibition in a very wet Milan, you couldn’t move for booths expounding on the capabilities of the world’s manufacturing, services, packaging and ingredients players. Some of these companies formerly considered themselves to be Contract Research Organisations (CROs) or CMOs (Contract Manufacturing Organisations) but now proudly display the letters CDMO (Contract Development […]
Analogue forecasting: the power of the past to predict the future
Launching a first-in-class drug is high on the wish list of most pharma companies, but achieving that goal is not without its challenges. While patient demand for innovative therapies will always be high, modelling their impact on the treatment landscape is an uncertain business and the stakes are too high to rely on little more […]
Meet the Evaluate Team: Penny Wills
Penny Wills joined the Evaluate team through its acquisition of J+D Forecasting at the start of 2024. As a seasoned forecasting implementation expert, Penny’s role encompasses working closely with clients to understand their requirements for their forecasting models and ensuring successful delivery by working with stakeholders across the team. I grabbed some time with Penny […]
Join the Discussion: Dealmaking, Innovation and Geopolitics in Pharma
BIO-Europe took place last week in Stockholm. It’s one of the last big biopharma events of the year and a great time to take stock of where the industry stands as the new year approaches. I was at the convention, taking part in a fireside chat to discuss global innovation trends. Also featuring on the […]
Mastering the Move from Phase III to Launch
The journey from Phase III clinical trials to a successful product launch is both exciting and challenging. It’s a crucial stage that sets the foundation for how a new product will perform in the market. But with resources often already allocated to established brands, and the need for precise forecasting and planning, launching a new […]
Meet the Evaluate Team: Andy Mills
If you work with Evaluate, you’ll probably be familiar with our delightful Customer Success team. They’re the people who help ensure that our customers can use our solutions to navigate the pharma landscape, and answer their key questions to help them make the right decisions about their business. One member of this team is Andy […]
